The consensus narrative frames Merck as a one-product company facing an existential patent cliff in 2028. Wefundamentally disagree with this characterization. Merck is executing one of the most ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes ...

So far, the most headline-making Olympic news has nothing to do with gold medals. But rather, what some male Olympians are willing to do for them. Enter: Penisgate. Mere days after the Olympics began, ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

Lev Facher covers the U.S. addiction and overdose crisis. ROCHESTER, N.H. — Megan Merrill paused, mid-hike, as she surveyed the steep drop before her. She was standing on a five-foot snow drift, icy ...

A Columbus Division of Police detective was contacted on Feb. 6 by staff at Nationwide Children’s about a mother accused of abusing her child, our news partners at WBNS reported. The child was a ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

Are male ski jumpers injecting a specific kind of acid into their penises in order to gain a small advantage over their competitors? Maybe. But if so, don’t worry, Winter Olympics officials are on it.

The last time I spoke about AbbVie Inc. (ABBV) it was in a Seeking Alpha article entitled as "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating." For this article I ...

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...